Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice

被引:41
作者
Hung, C-F
Tsai, Y-C
He, L.
Coukos, G.
Fodor, I.
Qin, L.
Levitsky, H.
Wu, T-C
机构
[1] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
[2] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA
[3] Univ Penn, Abramson Canc Res Inst, Philadelphia, PA 19104 USA
[4] Ctr Res Reprod & Womens Hlth, Philadelphia, PA USA
[5] Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA
[6] Loma Linda Univ, Dept Microbiol, Ctr Mol Biol & Gene Therapy, Loma Linda, CA 92350 USA
[7] Johns Hopkins Med Inst, Dept Obstet & Gynecol, Baltimore, MD 21205 USA
[8] Johns Hopkins Med Inst, Dept Mol Microbiol, Baltimore, MD 21205 USA
[9] Johns Hopkins Med Inst, Dept Immunol, Baltimore, MD 21205 USA
关键词
vaccinia virus; ovarian cancer; luciferase; antitumor effects;
D O I
10.1038/sj.gt.3302840
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vaccinia virus has been shown to efficiently infect tumor cells. Therefore, vaccinia virus represents a potentially safe and effective antitumor agent against ovarian cancer. Here, we assessed the ability of vaccinia virus to preferentially infect and control both human and murine ovarian tumors in vivo. We used the non-invasive luminescence imaging system to monitor the infection and suppression of ovarian tumors by vaccinia in live mice. Our data indicated that vaccinia was able to effectively infect and kill both human and murine ovarian tumors. Vaccinia virus administered to mice intraperitoneally was specifically targeted to the murine or human ovarian tumors and led to antitumor responses. These findings suggest that vaccinia virus is capable of selectively targeting and controlling ovarian tumors. Thus, intraperitoneal injection with vaccinia virus may provide a potentially effective strategy for treating advanced-stage ovarian cancers.
引用
收藏
页码:20 / 29
页数:10
相关论文
共 31 条
[1]   Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].
Amara, RR ;
Villinger, F ;
Altman, JD ;
Lydy, SL ;
O'Neil, SP ;
Staprans, SI ;
Montefiori, DC ;
Xu, Y ;
Herndon, JG ;
Wyatt, LS ;
Candido, MA ;
Kozyr, NL ;
Earl, PL ;
Smith, JM ;
Ma, HL ;
Grimm, BD ;
Hulsey, ML ;
Miller, J ;
McClure, HM ;
McNicholl, JM ;
Moss, B ;
Robinson, HL .
SCIENCE, 2001, 292 (5514) :69-74
[2]  
BAUM M, 1990, ADJUVANT THERAPY CAN, V1, P269
[3]   Low-dose vaccinia virus-mediated cytokine gene therapy of glioma [J].
Chen, B ;
Timiryasova, TM ;
Haghighat, P ;
Andres, ML ;
Kajioka, EH ;
Dutta-Roy, R ;
Gridley, DS ;
Fodor, I .
JOURNAL OF IMMUNOTHERAPY, 2001, 24 (01) :46-57
[4]   Recognition of vaccinia virus-infected cells by human natural killer cells depends on natural cytotoxicity receptors [J].
Chisholm, SE ;
Reyburn, HT .
JOURNAL OF VIROLOGY, 2006, 80 (05) :2225-2233
[5]   Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A [J].
Conejo-Garcia, JR ;
Benencia, F ;
Coureges, MC ;
Kang, E ;
Mohamed-Hadley, A ;
Buckanovich, RJ ;
Holtz, DO ;
Jenkins, A ;
Na, HN ;
Zhang, L ;
Wagner, DS ;
Katsaros, D ;
Caroll, R ;
Coukos, G .
NATURE MEDICINE, 2004, 10 (09) :950-958
[6]  
*EARL BREAST CANC, 1992, LANCET, V339, P1
[7]   Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model [J].
Fodor, I ;
Timiryasova, T ;
Denes, B ;
Yoshida, J ;
Ruckle, H ;
Lilly, M .
JOURNAL OF UROLOGY, 2005, 173 (02) :604-609
[8]  
Gnant MFX, 1999, CANCER RES, V59, P3396
[9]  
Gnant MFX, 1999, ANN SURG, V230, P352, DOI 10.1097/00000658-199909000-00008
[10]   Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases [J].
Gnant, MFX ;
Noll, LA ;
Irvine, KR ;
Puhlmann, M ;
Terrill, RE ;
Alexander, HR ;
Bartlett, DL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (20) :1744-1750